SCHEMBL25913732

SCHEMBL25913732

CCC(=O)NCCOCCOCCOCCN1CCN(C(C)C)CC1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 2/20 0.44
▸ TP53 P04637 1/20 0.44
▸ DRD2 P14416 2/20 0.40
▸ DRD3 P35462 2/20 0.40
▸ MEN1 O00255 2/20 0.40
▸ KMT2A Q03164 2/20 0.40
▸ SIGMAR1 Q99720 1/20 0.39
▸ ALDH1A1 P00352 3/20 0.37
▸ LMNA P02545 1/20 0.37
▸ GAA P10253 1/20 0.37
▸ MAPT P10636 1/20 0.37
▸ MAPK1 P28482 1/20 0.37
▸ FPR3 P25089 1/20 0.36
▸ FPR2 P25090 1/20 0.36
▸ KDM4E B2RXH2 1/20 0.36
▸ HTR4 Q13639 1/20 0.35
▸ USP2 O75604 1/20 0.35
▸ DAO P14920 1/20 0.35
▸ TDP1 Q9NUW8 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25477805 1.00 SMN1; SMN2 (0.44) SMN1; SMN2TP53DRD2DRD3MEN1
SCHEMBL21106866 0.86 MEN1 (0.41) SMN1; SMN2TP53DRD2MEN1KMT2A
SCHEMBL24765441 0.86 MEN1 (0.41) SMN1; SMN2TP53DRD2MEN1KMT2A
SCHEMBL22856287 0.85 MEN1 (0.47) SMN1; SMN2TP53DRD2MEN1KMT2A
SCHEMBL21107592 0.85 MEN1 (0.47) SMN1; SMN2TP53DRD2MEN1KMT2A
SCHEMBL23945709 0.85 TP53 (0.41) SMN1; SMN2TP53DRD2MEN1KMT2A
SCHEMBL24508674 0.84 ACHE (0.45) SMN1; SMN2TP53DRD2DRD3MEN1
SCHEMBL23709496 0.84 TP53 (0.49) SMN1; SMN2TP53DRD2DRD3MEN1
SCHEMBL21107025 0.83 MEN1 (0.45) SMN1; SMN2TP53DRD2MEN1KMT2A
SCHEMBL25972108 0.83 TP53 (0.40) SMN1; SMN2TP53MEN1KMT2ASIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230234936-A1 COMPOUND FOR TARGETING AND DEGRADING PROTEIN, AND PREPARATION METHOD THEREFOR AND USE THEREOF LEADINGTAC PHARMACEUTICAL (SHAOXING) CO., LTD. (CN) 2023-07-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230234936-A1 COMPOUND FOR TARGETING AND DEGRADING PROTEIN, AND PREPARATION METHOD THEREFOR AND USE THEREOF IRAK4, IRAK2, IRAK1 SMN1; SMN2 3854/4885TP53 701/4885DRD2 4831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback